Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00006262 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00231829 | A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers | terminated | Phase 2 | 23 | Mark H. EinsteinOTHER | 1 | Apr 24, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | terminated | Phase 2 | 38 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Apr 18, 2007 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00220532 | Folate and Protection Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 180 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2013source: clinicaltrials